• Renewal of Our Value in Health Mission and Policy As We Enter Our Fourth Year

    Jan 1, 2001, 00:00

  • Pharmaceutical Regulation- The Early Experience of the NHS National Institute for Clinical Excellence (NICE) Appraisal Process—Where Are We Headed? Presented at the ISPOR 5th Annual International Meeting, Crystal City, VA, 24 May 2000

    Jan 1, 2001, 00:00

  • Predictors of Long-term Persistence on Statins in a Subsidized Clinical Population

    Nov 1, 2000, 00:00

  • Short–run Associations Between Medical Care Expenditures and Adherence to Clinical Practice Guideline-based Measures for Diabetes

    Nov 1, 2000, 00:00

  • Deep Vein Thrombosis- Cost-effective Management of a Major Health Problem

    Nov 1, 2000, 00:00

  • Economic Evaluation of Enoxaparin vs. Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

    Nov 1, 2000, 00:00

  • Introduction to Diabetes Special Issue of Value in Health

    Nov 1, 2000, 00:00

  • Health-Related Quality of Life Measurement in Type 2 Diabetes

    Nov 1, 2000, 00:00

  • Economic Evaluations Relating to Diabetes- A Descriptive Review and Their Compliance with Guidance

    Nov 1, 2000, 00:00

  • The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex)- A Core Model with an Application Using Swedish Cost Data

    Nov 1, 2000, 00:00

  • Health-related Quality of Life in Type 2 Diabetes (TARDIS-2)

    Nov 1, 2000, 00:00

  • Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy

    Nov 1, 2000, 00:00

  • Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France- A Cost Analysis

    Nov 1, 2000, 00:00

  • Epidemiology and Clinical Presentation of Type 2 Diabetes

    Nov 1, 2000, 00:00

  • Economic Evaluation of Enoxaparin as Postdischarge Prophylaxis for Deep Vein Thrombosis (DVT) in Elective Hip Surgery

    Nov 1, 2000, 00:00

  • GU2- HEALTH CARE WORKERS EXPECTATIONS

    Sep 1, 2000, 00:00

  • PMDP3- THE FRENCH HEALTH UTILITIES INDEX MARK 3

    Sep 1, 2000, 00:00

  • PMDQ1- GENERAL POPULATION-BASED QUALITY OF LIFE MEASUREMENTS USING THE EQ-5D QUESTIONNAIRE

    Sep 1, 2000, 00:00

  • PMDE1- SOCIETAL IMPACT OF LOST EARNINGS ASSOCIATED WITH AGE-RELATED MACULOPATHY

    Sep 1, 2000, 00:00

  • PAO1- COST-EFFECTIVENESS ANALYSIS OF NSAIDS VS COX-2 SPECIFIC INHIBITORS AND NSAIDS WITH CO-TREATMENTS TO PREVENT Gl TOXICITY IN THE TREATMENT OF RA

    Sep 1, 2000, 00:00

  • NR2- QUALITY OF LIFE AFTER SUBARACHNOID HEMORRHAGE IN RELATION TO RISK ESTIMATION BEFORE SURGERY

    Sep 1, 2000, 00:00

  • PAO3- DIRECT MEDICAL COST OF CHRONIC POLYARTHRITIS IN GERMANY

    Sep 1, 2000, 00:00

  • RS2- SYMPTOM-BASED OUTCOME MEASURES FOR ASTHMA

    Sep 1, 2000, 00:00

  • PCV29- SUPPORTING IMPLEMENTATION OF PRESCRIPTION GUIDELINES IN MEDICAL WARDS- A RANDOMIZED TRIAL

    Sep 1, 2000, 00:00

  • PGS5- APPRAISAL OF ERECTILE DYSFUNCTION- WHOSE VALUES SHOULD BE USED?

    Sep 1, 2000, 00:00

  • AO2- GENERIC AND DISEASE-SPECIFIC HEALTH RELATED QUALITY OF LIFE MEASUREMENTS IN 127 RHEUMATOID ARTHRITIS AND 167 OSTEOARTHRITIS PATIENTS IN HUNGARY

    Sep 1, 2000, 00:00

  • CV4- THE INFLUENCE OF NON-CARDIAC VASCULAR DISEASE ON THE COST-EFFECTIVENESS OF SCREENING FOR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (LVSD)

    Sep 1, 2000, 00:00

  • PNR5- THE LONG-TERM ECONOMIC IMPACT OF TREATING ALZHEIMERS PATIENTS IN SWEDEN WITH GALANTAMINE

    Sep 1, 2000, 00:00

  • PMDP1- WILLINGNESS TO PAY FOR AVOIDING ADVERSE EFFECTS OF DRUGS

    Sep 1, 2000, 00:00

  • PRS3- EUROQOL EQ-5D- DISCRIMINANT VALIDITY IN RESPIRATORY DISEASE

    Sep 1, 2000, 00:00

  • PMDQ3- HEALTH-RELATED QUALITY OF LIFE AMONG FRENCH PATIENTS HOSPITALIZED IN INTERNAL MEDICINE

    Sep 1, 2000, 00:00

  • PNH6- ANTIPSYCHOTIC TREATMENT, ADVERSE EVENTS AND HEALTH-RELATED QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PRS9- PROBLEMATIC ISSUES OF THE QUALITY OF ASTHMA MANAGEMENT IN RURAL AREAS IN GREECE

    Sep 1, 2000, 00:00

  • PCV9- PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AND FATAL PULMONARY EMBOLISM IN KNEE ARTHROPLASTIES- A COST-EFFECTIVENESS STUDY

    Sep 1, 2000, 00:00

  • PRS7- AN ECONOMIC IMPACT OF A DUR INTERVENTION ON THE PHARMACOLOGICAL MANAGEMENT OF ASTHMA IN CHILDREN

    Sep 1, 2000, 00:00

  • PNR7- COST-EFFECTIVENESS ANALYSIS OF ENTACAPONE IN ADVANCED PARKINSONS DISEASE A MARKOV PROCESS ANALYSIS

    Sep 1, 2000, 00:00

  • PMH15- ECONOMIC EVALUATION OF REBOXETINE FOR TREATING MAJOR DEPRESSION

    Sep 1, 2000, 00:00

  • PMDP4- THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES

    Sep 1, 2000, 00:00

  • PCV5- ECONOMIC EVALUATION OF RAMIPRIL IN THE TREATMENT OF PATIENTS AT HIGH RISK OF CARDIOVASCULAR EVENTS

    Sep 1, 2000, 00:00

  • PCV1- THE ATRIAL FIBRILLATION ANTITHROMBOSIS MODEL (AFAM)- A GENERAL-PURPOSE TOOL FOR ANALYSIS, POLICY-MAKING, AND EDUCATION

    Sep 1, 2000, 00:00

  • PNR6- SUBJECTIVE AND OBJECTIVE QUALITY OF LIFE CHANGE SCORES IN A SHORT-TERM EPILEPSY STUDY

    Sep 1, 2000, 00:00

  • PID7- MULTITHERAPIES- TOWARDS COST-SAVING STRATEGIES IN REAL LIFE?

    Sep 1, 2000, 00:00

  • CV2- EFFECTIVENESS AND COST-EFFECTIVENESS OF EPTIFIBATIDE IN INDIVIDUAL PATIENTS WITH ACUTE CARDIAC ISCHEMIA- THE IMPORTANCE OF RISK STRATIFICATION

    Sep 1, 2000, 00:00

  • CV6- A MULTICENTER STUDY OF PHARMACIST DIRECTED INTERVENTIONS IN DYSLIPIDEMIA THERAPY

    Sep 1, 2000, 00:00

  • PCN12- CHANGES IN OUTPATIENT DRUG COSTS FOR CANCER PATIENTS, 1995 vs 1998

    Sep 1, 2000, 00:00

  • PGU3- DECISION ANALYSIS OF OMEPRAZOLE VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION FOR TREATING PATIENTS WITH SEVERE GASTROESOPHAGEAL REFLUX DISEASE

    Sep 1, 2000, 00:00

  • PID6- CANADIAN COST-EFFECTIVENESS OF COMBINATION RIBAVIRIN/INTERFERON ALPHA-2B THERAPY FOR TREATMENT-NAIVE VIRAL HEPATITIS C

    Sep 1, 2000, 00:00

  • PMDP2- CONSUMER USE OF THE INTERNET FOR HEALTHCARE INFORMATION

    Sep 1, 2000, 00:00

  • ID3- PRELIMINARY EVALUATION OF THE CLINICAL AND ECONOMIC BENEFITS OF UNIVERSAL VARICELLA VACCINATION OF CHILDREN IN GERMANY

    Sep 1, 2000, 00:00

  • CH1- COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER

    Sep 1, 2000, 00:00

  • PGU17- FACTORS ASSOCIATED WITH SELECTING MEDICATION TO TREAT PATIENTS NEWLY DIAGNOSED WITH OVERACTIVE BLADDER

    Sep 1, 2000, 00:00

  • CN3- COST-SAVINGS FOR CAPECITABINE DUE TO ORAL ADMINISTRATION IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER

    Sep 1, 2000, 00:00

  • PMDH3- THE USE OF SURROGATE ENDPOINT DATA IN EVALUATING TREATMENT EFFICACY- IMPACT ON DECISION-MAKING AND EXPENDITURE WITHIN THE AUSTRALIAN PHARMACEUTICAL BENEFITS SCHEME

    Sep 1, 2000, 00:00

  • PCV23- VARIATION IN COSTS OF TREATING HYPERCHOLESTEROLEMIC PATIENTS IN FRANCE

    Sep 1, 2000, 00:00

  • CH2- RELATING QUALITY ADJUSTED LIFE YEARS TO CONTINGENT VALUATION- ACUTE VERSUS CHRONIC ILLNESSES

    Sep 1, 2000, 00:00

  • DB2- AGGREGATION OF WILLINGNESS-TO-PAY MEASURED IN DECOMPOSED SCENARIOS

    Sep 1, 2000, 00:00

  • PMDM2- GUIDING PRINCIPLES TO COMPARE THE EFFICACY OF NOVEL DRUGS USING RCT MATCHED ARM COMPARISONS

    Sep 1, 2000, 00:00

  • CV1- IS QUALITY OF LIFE A VALID OUTCOME FOR VARICOSE VEINS SURGERY? RESULTS OF AN INTERNATIONAL EPIDEMIOLOGICAL STUDY

    Sep 1, 2000, 00:00

  • PGU1- IS HEALTH-RELATED QUALITY OF LIFE (HRQL) IMPROVED BY GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) DRUGS?

    Sep 1, 2000, 00:00

  • PDB5- THE ECONOMIC BURDEN OF TYPE 2 DIABETES ON THE INDIVIDUAL

    Sep 1, 2000, 00:00

  • PCV8- HOSPITALIZATION COSTS AFTER FIRST ACUTE CORONARY SYNDROME- A COMBINED MODEL APPROACH

    Sep 1, 2000, 00:00

  • PGU1O- IRRITABLE BOWEL SYNDROME (IBS) IN GERMANY- A COST OF ILLNESS STUDY

    Sep 1, 2000, 00:00

  • PCN14- THE USE OF TRANSDERMAL FENTANYL (FEN) VERSUS MORPHINE (MOR) IN CANCER PAIN PATIENTS IN ISRAEL

    Sep 1, 2000, 00:00

  • PMDE2- THE COST OF GLAUCOMA TREATMENT IN POLAND-RESULTS FROM OBSERVATIONAL STUDY

    Sep 1, 2000, 00:00

  • PCU16- ADAPTING A US COST-OFFSET ECONOMIC MODEL FOR OVERACTIVE BLADDER FOR THE EUROPEAN MARKETPLACE

    Sep 1, 2000, 00:00

  • PNR2- THE ROLE OF COGNITIVE METHODS IN THE DESIGN OF CONJOINT ANALYSIS TO EVALUATE EPILEPSY TREATMENTS

    Sep 1, 2000, 00:00

  • PCV11- DETERMINANTS OF COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH OPEN HEART SURGERY

    Sep 1, 2000, 00:00

  • PRS12- COST OF ILLNESS ON PATIENTS IN A PUBLIC HOSPITAL WITH SEVERE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAY DISEASE

    Sep 1, 2000, 00:00

  • PGU15- COSTS AND RESOURCES ASSOCIATED WITH THE TREATMENT OF OVERACTIVE BLADDER USING RETROSPECTIVE MEDICAL CARE CLAIMS DATA

    Sep 1, 2000, 00:00

  • PID1- ASSOCIATED OUTCOMES OF INFLUENZA-LIKE-ILLNESS AND CLINICAL INFLUENZA IN ITALY

    Sep 1, 2000, 00:00

  • PMH5- IMPACT OF AMISULPRIDE ON HEALTH CARE RESOURCES IN SCHIZOPHRENIA- PRELIMINARY RESULTS OF A FRENCH STUDY

    Sep 1, 2000, 00:00

  • PCV27- TREATMENT OF CHRONIC HEART FAILURE (CHF)- IMPROVING SURVIVAL BUT NOT HEALTH-RELATED QUALITY OF LIFE (HRQL)

    Sep 1, 2000, 00:00

  • RS1- COMPARISON OF IMPUTATION METHODS FOR MISSING ASTHMA QUALITY OF LIFE DATA

    Sep 1, 2000, 00:00

  • PRS18- USE OF PHARMACOTHERAPY AS AN ASTHMA SEVERITY MEASURE IN A RETROSPECTIVE ANALYSIS

    Sep 1, 2000, 00:00

  • PCV15- ANTI-HYPERTENSIVE AGENTS AND THE RISK OF HIP OR WRIST FRACTURES IN AN OTHERWISE HEALTHY COMMUNITY POPULATION

    Sep 1, 2000, 00:00

  • PMDM1- POWER AND SAMPLE SIZE CALCULATIONS FOR A CLINICAL TRIAL CONSIDERING COST-EFFECTIVENESS AND STATISTICAL ERRORS

    Sep 1, 2000, 00:00

  • PMH10- SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC TREATMENT AND COMPLIANCE IN SCHIZOPHRENIA

    Sep 1, 2000, 00:00

  • PCV24- THE COST OF REACHING LDL-C TARGETS IN SPAIN- A COMPARISON AMONG STATINS

    Sep 1, 2000, 00:00

  • PNR8- A CANADIAN ADAPTATION OF A DECISION ANALYTIC MODEL FOR THE ECONOMIC EVALUATION OF OPIOIDS FOR CHRONIC PAIN

    Sep 1, 2000, 00:00

  • DBS- A FIVE YEAR LONGITUDINAL ANALYSIS OF THE HEALTH BENEFITS OF TRANSITIONING TO INSULIN THERAPY SOONER IN THE MANAGEMENT OF NEWLY DIAGNOSED TYPE II DIABETICS

    Sep 1, 2000, 00:00

  • PMH4- CLINICAL, HUMANISTIC, AND ECONOMIC OUTCOMES ASSOCIATED WITH LONG-TERM TREATMENT OF MANIA WITH OLANZAPINE

    Sep 1, 2000, 00:00

  • PMH11- DEINSTITUTIONALIZATION MODEL IN SCHIZOPHRENIA- COST-CONSEQUENCES OF INTENSIVE CASE MANAGEMENT VERSUS STANDARD CASE MANAGEMENT

    Sep 1, 2000, 00:00

  • CV3- IMPACT OF CARVEDILOL ON INPATIENT RESOURCE USE AND COSTS IN HEART FAILURE

    Sep 1, 2000, 00:00

  • PMDE6- EVALUATION OF THE VALIDITY OF RETROSPECTIVE QOL OUTCOMES

    Sep 1, 2000, 00:00

  • PMDQ2- CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98- BY DECLARED REGULARITY OF PHARMACEUTICAL DRUG INTAKE

    Sep 1, 2000, 00:00

  • PCH11- PAYER COSTS OF PANCREATIC CANCER IN A NONELDERLY MEDICAID POPULATION

    Sep 1, 2000, 00:00

  • PDB6- THE FINANCIAL EFFECTS OF INTERFACE AGREEMENTS FOR DIABETES MELLITUS- SOCIOECONOMIC RELEVANCE OF INTENSIVE CONTROLLED INSULIN THERAPY WITH INSULIN LISPRO COMPARED TO REGULAR HUMAN INSULIN

    Sep 1, 2000, 00:00

  • PGU7- IN FINLAND, SWEDEN AND THE UK, ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH REFLUX OESOPHAGITIS

    Sep 1, 2000, 00:00

  • PRS1- TO COMPARE AND CONTRAST THE QUALITY OF LIFE (QOL) OF INDIVIDUALS WITH CHRONIC BRONCHITIS, DURING THE STABLE PHASE AND ACUTE EXACERBATIONS

    Sep 1, 2000, 00:00

  • PRS4- A HEALTH ECONOMIC MODEL TO DESCRIBE THE CURRENT AND EXPECTED BURDEN OF COPD

    Sep 1, 2000, 00:00

  • PDB4- EFFECT OF A POLICY CHANGE ON USE OF BLOOD GLUCOSE MONITORS BY DIABETICS WITH MEDICARE COVERAGE

    Sep 1, 2000, 00:00

  • PCV12- A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL IN THE TREATMENT OF HYPERTENSION IN EUROPE

    Sep 1, 2000, 00:00

  • PDB7- HEALTH RELATED QUALITY OF LIFE IN TYPE 2 DIABETES

    Sep 1, 2000, 00:00

  • PID10- COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTIC PROPHYLAXIS IN INTRA-ABDOMINAL SURGERY

    Sep 1, 2000, 00:00

  • PMDH1- NICE REQUIREMENTS FOR COST-EFFECTIVENESS EVIDENCE- POTENTIAL SAMPLE SIZE IMPLICATIONS OF GENERATING TRIAL-BASED EVIDENCE

    Sep 1, 2000, 00:00

  • PMDH6- AN ECONOMIC EVALUATION OF PHARMACEUTICAL COST CONTAINMENT POLICIES IN ALBERTA, CANADA

    Sep 1, 2000, 00:00

  • PDB1- VARIATIONS IN MEDICATION UTILIZATION IN AN OLDER DIABETIC POPULATION

    Sep 1, 2000, 00:00

  • PMH13- THE MEDICAL COSTS OF DEMENTIA IN BELGIUM- RESULTS OF THE NADES STUDY

    Sep 1, 2000, 00:00

  • PRS6- QUALITY OF LIFE AND TREATMENT SATISFACTION MEASUREMENT WITH ASTHMA PATIENTS- RESULTS FROM A COMPREHENSIVE LITERATURE REVIEW

    Sep 1, 2000, 00:00

  • PNR3- A COST MINIMIZATION MODEL FOR 2-1 THERAPEUTIC INTERCHANGE PROTOCOLS OF MEDICATIONS WITH HIGHLY VARIABLE DOSING REGIMENS

    Sep 1, 2000, 00:00

  • PAO2- A COST-COST STUDY COMPARING ETANERCEPT WITH INFLIXIMAB IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2000, 00:00

  • PAO10- ANNUAL COST OF TREATING CARPAL TUNNEL SYNDROME IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • MD2- MEASURING REDUCED PRODUCTIVITY DURING PAID LABOR

    Sep 1, 2000, 00:00

  • PGU5- THE BURDEN OF ILLNESS OF IRRITABLE BOWEL SYNDROME (IBS) USING THE ROME II CRITERIA

    Sep 1, 2000, 00:00

  • PID11- THE PEACE PROJECT (PRESCRIPTION AND EFFECTIVENESS OF ANTIBIOTIC IN CLINICAL EXPERIENCE)- RESULTS OF THE FEASIBILITY STUDY

    Sep 1, 2000, 00:00

  • PGU6- DEVELOPMENT AND INITIAL PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-QUALITY OF LIFE INSTRUMENT (PAGI-QOL) IN Gl PATIENTS

    Sep 1, 2000, 00:00

  • PCN6- QUALITY OF LIFE ASSESSMENT OF DOCETAXEL TREATED PATIENTS IN ADVANCED BREAST CANCER

    Sep 1, 2000, 00:00

  • GU3- ERADICATION OF HELICOBACTER PYLORI TO PREVENT PEPTIC ULCERS PRIOR TO NSAID THERAPY-A COST-EFFECTIVENESS ANALYSIS

    Sep 1, 2000, 00:00

  • PCN5- EVALUATION OF THREE DIFFERENT METHODS OF ASSESSING WILLINGNESS TO PAY FOR A NEW DRUG IN THE GENERAL POPULATION

    Sep 1, 2000, 00:00

  • PCV7- INCREMENTAL COST-EFFECTIVENESS RATIO IN ESTIMATION SOME HYPOTENSIVE DRUGS

    Sep 1, 2000, 00:00

  • PGU18- PREVALENCE OF BLADDER CONTROL PROBLEMS IN A LARGE GERMAN POPULATION SAMPLE

    Sep 1, 2000, 00:00

  • PID2- PHARMACOECONOMIC EVALUATION OF IMMUNOPROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK INFANTS

    Sep 1, 2000, 00:00

  • PAO7- COST-OF-ILLNESS STUDIES IN GERMANY WITH OSTEOPOROSIS AS EXAMPLE

    Sep 1, 2000, 00:00

  • PCV3- THE COST-EFFECTIVENESS OF TREATING CHLAMYDIA PNEUMONIAE INFECTION FOR THE PREVENTION OF CORONARY HEART DISEASE

    Sep 1, 2000, 00:00

  • PGS1- ALOPECIA, PSYCHOLOGICAL DISTRESS AND QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PCV6- GENDER DIFFERENCES IN THE QUALITY OF LIFE AND COMPLIANCE WITH ROUTINE TREATMENT OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY

    Sep 1, 2000, 00:00

  • NR1- PATIENTS REPORTED HEALTH STATUS AND UTILITIES FOR AMYOTROPHIC LATERAL SCLEROSIS

    Sep 1, 2000, 00:00

  • PCV18- COST-EFFECTIVENESS OF PREVENTION OF ATHEROTHROMBOTIC DISEASE WITH ASPIRIN VERSUS CLOPIDOGREL IN GREECE

    Sep 1, 2000, 00:00

  • PID3- COST-EFFECTIVENESS OF HEPATITIS B VACCINATION IN THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PCN4- ECONOMIC CONSEQUENCES OF DIFFERENCES IN THE ADVERSE-EVENTS (AE) PROFILE OF CAPECITABINE vs. MAYO CLINIC (M) -REGIMEN IN PREVIOUSLY UNTREATED ADVANCED/ METASTATIC COLORECTAL CANCER.

    Sep 1, 2000, 00:00

  • PMDH9- ATLAS OF AVOIDABLE DEATHS IN ITALY

    Sep 1, 2000, 00:00

  • PMDE3- COST-EFFECTIVENESS ANALYSIS OF CONTINOUS TERBINAFINE VS INTERMITTENT ITRACONAZOLE IN THE TREATMENT OF TOENAIL ONYCHOMYCOSIS IN POLAND

    Sep 1, 2000, 00:00

  • PGU2- DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN Gl PATIENTS

    Sep 1, 2000, 00:00

  • MH3- VALIDATION OF A METHODOLOGY FOR ESTIMATING PRODUCTIVITY GAINS FROM IMPROVEMENTS IN HAM-D SCORES

    Sep 1, 2000, 00:00

  • PRS8- TREATMENT AND ASSOCIATED COSTS OF NEWLY DIAGNOSED COPD PATIENTS IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • PRS16- ECONOMIC IMPACT OF THE RESPIRATORY SYNCYTIAL VIRUS DISEASE, FRENCH SOCIETAL PERSPECTIVE

    Sep 1, 2000, 00:00

  • PMDH1O- REIMBURSED DRUG REGULATION- COMPARING TWO MODELS FOR CONTROL DRUGS CONSUMPTION IN ISRAEL USING PERMEATION COEFFICIENT PARAMETER.

    Sep 1, 2000, 00:00

  • PMDM3- PROJECTING ECONOMIC RESULTS OF A EUROPEAN TRIAL TO THE UNITED STATES- ISSUES AND METHODS

    Sep 1, 2000, 00:00

  • PMH3- GLOBAL INDEX OF SAFETY (GIS)- A NEW INSTRUMENT TO ASSESS DRUG SAFETY- APPLICATION TO A PROSPECTIVE PHARMACOEPIDEMIOLOGICAL STUDY (EFESO)

    Sep 1, 2000, 00:00

  • PMH8- PHARMACOECONOMIC MODELLING IN DEPRESSION- AID OR TRAP

    Sep 1, 2000, 00:00

  • PNR1- COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

    Sep 1, 2000, 00:00

  • PMDH8- DO DECISION-MAKERS FIND ECONOMIC EVALUATIONS USEFUL? RESULTS OF FOCUS GROUP RESEARCH IN THE UK

    Sep 1, 2000, 00:00

  • PGS6- METHODOLOGICAL ISSUES IN EVALUATING CONCEPTUAL EQUIVALENCE- APPLICATION TO THE WOMENS HEALTH QUESTIONNAIRE (WHQ)

    Sep 1, 2000, 00:00

  • PRS5- COST-EFFECTIVENESS OF EMEDASTINE VERSUS LEVOCABASTINE IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS

    Sep 1, 2000, 00:00

  • PID12- THE IMPACT OF PRICE ELASTICITY OF DEMAND ON CONSUMPTION-AMPICILLIN/ AMOXICILLIN MARKET SURVEY IN BULGARIA, 1995 AND 1999

    Sep 1, 2000, 00:00

  • GS1- AN INVESTIGATION OF FACTORS USED BY PATIENTS FOR DRUG TREATMENT DECISION-MAKING- AN EXAMINATION OF THERAPY OPTIONS FOR ERECTILE DYSFUNCTION

    Sep 1, 2000, 00:00

  • PGU8- ANALYSIS OF THE DIRECT COST GENERATED BY INFLIXIMAB TO NORMALIZE QUALITY OF LIFE IN PATIENTS WITH CROHNS DISEASE

    Sep 1, 2000, 00:00

  • PCV13- COSTS ASSOCIATED WITH HEALTH SERVICES UTILIZATION IN PATIENTS WITH VARICOSE VEINS

    Sep 1, 2000, 00:00

  • PID8- COST-EFFECTIVENESS OF CIPROFLOXACIN HYDROCORTISON IN THE TREATMENT OF ACUTE OTITIS EXTERNA

    Sep 1, 2000, 00:00

  • PCN7- FAMILY CAREGIVING COSTS FOR THE ELDERLY WITH CANCER- ESTIMATES FROM A REPRESENTATIVE SAMPLE OF THE UNITED STATES

    Sep 1, 2000, 00:00

  • PCN9- AN APPROACH TO DESIGNING A MULTINATIONAL MODEL FOR THE CURRENT TREATMENT OF BREAST CANCER

    Sep 1, 2000, 00:00

  • PCV22- COST-EFFECTIVENESS OF HMG-CoA REDUCTASE INHIBITORS AND FIBRATES THERAPY IN ELDERLY WOMEN WITH CORONARY ARTERY DISEASE

    Sep 1, 2000, 00:00

  • PMH17- COST OF TREATING SIDE EFFECTS OF SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRIs) IN A HEALTH MAINTENANCE ORGANIZATION (HMO)

    Sep 1, 2000, 00:00

  • NR3- ECONOMIC EVALUATION OF TRANSDERMAL FENTANYL IN THE TREATMENT OF CHRONIC NON-CANCER PAIN IN DENMARK

    Sep 1, 2000, 00:00

  • PAO4- COX-II INHIBITORS AND NSAIDS- FINDINGS OF A NICE SUBMISSION

    Sep 1, 2000, 00:00

  • PGS4- PRESENTATION OF THE 23-ITEM WOMENS HEALTH QUESTIONNAIRE (WHQ)- SCORING AND INTERPRETATION ISSUES

    Sep 1, 2000, 00:00

  • PCV28- SAVINGS ACHIEVED IN AN HMO SPONSORED PRIMARY CARE BASED DISEASE MANAGEMENT AND CASE MANAGEMENT INITIATIVE

    Sep 1, 2000, 00:00

  • PAO9- IS RESIDRONATE MORE COST-EFFECTIVE THAN ETIDRONATE FOR FRACTURE PREVENTION? A COST-UTILITY ANALYSIS

    Sep 1, 2000, 00:00

  • PCH1- PAMIDRONATE FOR BREAST CANCER PATIENTS WITH SKELETAL METASTASES- A MARKOV TREE-BASED COST-UTILITY ANALYSIS

    Sep 1, 2000, 00:00

  • PGU14- MODELLING OF AN ANTIOBESITY TREATMENT- COST-EFFECTIVENESS MODEL IN THE UK

    Sep 1, 2000, 00:00

  • PGS7- ISSUES IN USING CONJOINT ANALYSIS TO VALUE HEALTH CARE WITHIN CLINICAL STUDIES

    Sep 1, 2000, 00:00

  • ID2- COST-EFFECTIVENESS ANALYSIS OF HEXAVALENT MENINGOCOCCAL B OUTER-MEMBRANE-VESICLE VACCINE

    Sep 1, 2000, 00:00

  • PRS2- COST-EFFECTIVENESS ANALYSIS OF BASIC AND IMMUNOTROPIC THERAPY IN CHILDREN WITH BRONCHIAL ASTHMA

    Sep 1, 2000, 00:00

  • PCN15- A METHODOLOGY FOR IMPLEMENTING QUALITY-ADJUSTED DISEASE FREE SURVIVAL (QADFS) WITH MULTIDIMENSIONAL QUALITY OF LIFE (QoL) INSTRUMENTS IN CANCER TRIALS

    Sep 1, 2000, 00:00

  • MH1- PATTERNS OF USE OF ANTIDEPRESSANT AND CONCOMITANT PSYCHOTROPICS

    Sep 1, 2000, 00:00

  • PGS2- PHARMACOECONOMIC MODELING IN ASSISTED REPRODUCTION TECHNOLOGIES- RECOMBINANT FSH VERSUS URINARY FSH

    Sep 1, 2000, 00:00

  • PGU4- UTILIZATION AND COSTS OF GASTROINTESTINAL DRUGS IN RELATION TO HELICOBACTER-PYLORI ERADICATION; PHARMACOECONOMIC ANALYSIS FOR THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PMDM4- MEASUREMENTS OF HEALTH STATUS IN DENMARK

    Sep 1, 2000, 00:00

  • PMH14- COST OF CARE IN SCHIZOPHRENIA PATIENTS-RESULTS FROM THE NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

    Sep 1, 2000, 00:00

  • NH2- ATYPICAL ANTIPSYCHOTICS AND THE RISK OF DEVELOPING DIABETES

    Sep 1, 2000, 00:00

  • PMDE5- COST-EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF OCULAR HYPERTENSION AND PRIMARY OPEN ANGLE GLAUCOMA

    Sep 1, 2000, 00:00

  • MD3- A NEW INDEX APPROACH TO MEASURE THE BENEFITS OF DELAYING THE PROGRESSION TO BLINDNESS

    Sep 1, 2000, 00:00

  • PCV2O- ANNUAL COST OF TREATING HYPERLIPIDEMIA IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • GU1- THE WILLINGNESS TO PAY FOR REDUCED URGE INCONTINENCE

    Sep 1, 2000, 00:00

  • PRS1O- AGE AND GENDER DIFFERENCES IN UTILIZATION OF ASTHMA MEDICATION IN CHILDREN AND YOUNG ADULTS IN TAYSIDE, SCOTLAND

    Sep 1, 2000, 00:00

  • PDB3- USE OF BOOTSTRAP IN A COST-OF-ILLNESS STUDY TO DERIVE ACCURACY OF ESTIMATES

    Sep 1, 2000, 00:00

  • PCH2- THE LEVEL OF HAEMOGLOBIN (Hb) IN U.K. CANCER PATIENTS CORRELATES POSITIVELY WITH QUALITY OF LIFE (QoL)

    Sep 1, 2000, 00:00

  • PGU12- IN FINLAND, SWEDEN AND THE UK, ON DEMAND TREATMENT WITH ESOMEPRAZOLE IS COST-EFFECTIVE IN PATIENTS WITH GORD WITHOUT OESOPHAGITIS

    Sep 1, 2000, 00:00

  • PMDH4- DIFFERING LEVELS OF PATIENT SATISFACTION WITH PHARMACY SERVICES IN A MANAGED CARE ORGANIZATION

    Sep 1, 2000, 00:00

  • PGS3- AN ASSESSMENT OF THE RELATION BETWEEN SILDENAFIL USE AND QUALITY OF LIFE DIMENSIONS

    Sep 1, 2000, 00:00

  • MD1- AVOIDABLE HOSPITALIZATION- TRENDS AND ETHNIC VARIATIONS IN SINGAPORE, 1991-1998

    Sep 1, 2000, 00:00

  • PCV25- THE COST OF STROKE IN GREECE IN 1998

    Sep 1, 2000, 00:00

  • PGU9- EVALUATION OF THE DIRECT COST OF CARE FOR PATIENTS SUFFERING FROM HEMORRHOIDS

    Sep 1, 2000, 00:00

  • PRS14- ASTHMA AND ANTI-ASTHMA DRUG USE IN HUNGARY

    Sep 1, 2000, 00:00

  • PCN8- COST-UTILITY ANALYSIS OF SEVERAL SECOND-LINE CHEMOTHERAPY SCHEMES FOR PATIENTS WITH METASTATIC BREAST CANCER

    Sep 1, 2000, 00:00

  • PAO6- BUDGETARY IMPACT ANALYSIS FOR USE IN REIMBURSEMENT PROCESS OF ETANERCEPT IN MODERATE TO SEVERE RHEUMATOID ARTHRITIS

    Sep 1, 2000, 00:00

  • PRS15- OUTCOMES RESEARCH STUDY ASSESSING RESOURCE UTILIZATION FOR THE TREATMENT OF ASTHMA EXACERBATION IN PRIMARY CARE IN SPAIN

    Sep 1, 2000, 00:00

  • PCN3- COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC PAMIDRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND (COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS)

    Sep 1, 2000, 00:00

  • PCN13- MANAGEMENT OF LUNG CANCER IN FRANCE

    Sep 1, 2000, 00:00

  • PCV1O- RETROSPECTIVE MEDICAL RECORD REVIEW TO DETERMINE THE 'AT GOAL' PATIENTS WITH HYPERTENSION AND/OR DYSLIPIDEMIA

    Sep 1, 2000, 00:00

  • PGS8- ECONOMIC ASSESSMENT OF THE DIRECT SPECIFIC COST OF BENIGN PROSTATIC HYPERPLASIA IN FRANCE, HEALTH INSURANCE PERSPECTIVE

    Sep 1, 2000, 00:00

  • PCV4- COST-EFFECTIVENESS OF DOXAZOSIN IN COMBINATION THERAPY FOR HYPERTENSION TREATMENT IN DIABETIC PATIENTS IN THE UK

    Sep 1, 2000, 00:00

  • PAO5- THE COSTS OF RHEUMATOID ARTHRITIS- IS THERE A NEED FOR STANDARDIZATION OF METHODS?

    Sep 1, 2000, 00:00

  • PMH16- RELAPSE IN SCHIZOPHRENIA- COSTS AND QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • PHH7- TREATMENT PATTERNS OF PATIENTS WITH SCHIZOPHRENIA AND SCHIZO-AFFECTIVE DISORDER ACROSS 15 COUNTRIES

    Sep 1, 2000, 00:00

  • PHDH7- INTERNATIONAL COMPARISON OF PHARMACOECONOMIC GUIDELINES- CONSENSUS, DIVERGENCE AND PRACTICAL IMPLICATIONS

    Sep 1, 2000, 00:00

  • PCV19- TURKISH PHYSICIAN PRESCRIPTION PATTERNS FOR HYPERTENSION MANAGEMENT

    Sep 1, 2000, 00:00

  • PCV17- VARIABILITY IN ABCIXIMAB (REOPRO) USAGE- EVIDENCE-BASED OR BUDGET-DRIVEN?

    Sep 1, 2000, 00:00

  • AO3- QUALITY OF LIFE AFTER OSTEOPOROTIC FRACTURES IN DUTCH MEN AND WOMEN

    Sep 1, 2000, 00:00

  • PCN1O- COMPARISON OF COSTS AND EFFECTS OF PROPHYLACTIC CLODRONATE FOR THE PREVENTION OF SKELETAL RELATED EVENTS IN PATIENTS WITH ADVANCED BREAST CANCER IN POLAND

    Sep 1, 2000, 00:00

  • PCV2- POPULATION PROJECTIONS OF CARDIOVASCULAR DISEASE MORBIDITY AND MORTALITY ASSOCIATED WITH ROFECOXIBS EFFECT ON SYSTOLIC BLOOD PRESSURE

    Sep 1, 2000, 00:00

  • PMDQ4- CHANGE AND STATUS IN QUALITY OF LIFE (CASINQOL) IN NORTHERN SWEDEN IN 1997/98- PSYCHOMETRICS OF THE MINI QLCS ASSESSMENT BATTERY APPLIED

    Sep 1, 2000, 00:00

  • PRS13- ANNUAL COST OF TREATING RHINITIS IN A MANAGED CARE POPULATION

    Sep 1, 2000, 00:00

  • PID13- COST-EFFECTIVENESS OF GANCICLOVIR IN PREVENTION OF CYTOMEGALOVIRUS DISEASE AFTER LIVER TRANSPLANTATION- A BAYESIAN APPROACH

    Sep 1, 2000, 00:00

  • PGU13- ESOMEPRAZOLE IS COST-EFFECTIVE COMPARED WITH OMEPRAZOLE FOR THE ACUTE TREATMENT OF PATIENTS WITH NON-ENDOSCOPED GORD IN THE UK

    Sep 1, 2000, 00:00

  • PGU11- DEVELOPMENT AND PRELIMINARY PSYCHOMETRIC VALIDATION OF THE PATIENT ASSESSMENT OF UPPER GASTROINTESTINAL DISORDERS-SYMPTOM SEVERITY INDEX (PAGI-SYM) IN GASTROPARESIS

    Sep 1, 2000, 00:00

  • DB1- TWO-PART MODELS FOR DEMAND OF HOSPITAL TREATMENT IN TYPE II DIABETIC PATIENTS

    Sep 1, 2000, 00:00

  • GS3- THE VALUATION OF DISEASE-SPECIFIC HEALTH STATES TO FACILITATE ECONOMIC EVALUATION OF PHARMACEUTICALS

    Sep 1, 2000, 00:00

  • PRS17- EPIDEMIOLOGY AND COSTS OF BRONCHIAL ASTHMA AND CHRONIC BRONCHITIS IN GERMANY

    Sep 1, 2000, 00:00

  • PCV16- COST-EFFECTIVENESS OF LOW-MOLECULAR WEIGHT HEPARIN VERSUS ORAL ANTICOAGULANTS FOR SECONDARY PROPHYLAXIS OF VENOUS THROMBOEMBOLISM

    Sep 1, 2000, 00:00

  • ID1- MODELLING THE COSTS AND EFFECTS OF CMV MANAGEMENT STRATEGIES IN TRANSPLANT RECIPIENTS AS A SUPPORT FOR CURRENT AND FUTURE DECISION-MAKING

    Sep 1, 2000, 00:00

  • PDB2- COST-EFFECTIVENESS OF A NEW HUMAN DERMAL REPLACEMENT FOR THE TREATMENT OF DIABETIC FOOT ULCERS- THE CASE OF FRANCE

    Sep 1, 2000, 00:00

  • PRS11- IMPACT OF BRONCHIAL ASTHMA ON CHILDS QUALITY OF LIFE

    Sep 1, 2000, 00:00

  • GS2- DEVELOPMENT AND VALIDATION OF A TREATMENT SATISFACTION MODULE FOR USE WITH MENOPAUSAL WOMEN

    Sep 1, 2000, 00:00

  • AO1- IMPACT OF POST-FRACTURE TREATMENT COSTS AND MODEL TIME HORIZON ON COST-EFFECTIVENESS OF OSTEOPOROSIS THERAPIES

    Sep 1, 2000, 00:00

  • CV5- AN ECONOMIC EVALUATION OF TINZAPARIN COMPARED TO STANDARD HEPARIN IN TREATING PULMONARY EMBOLISM

    Sep 1, 2000, 00:00

  • PID9- PATIENTS COMPLIANCE AND COST-EFFECTIVENESS OF SELECTED ORAL ANTIBACTERIALS IN INPATIENT TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS

    Sep 1, 2000, 00:00

  • PMDH5- TEMPORAL TRENDS AND ETHNIC VARIATIONS IN AMENABLE MORTALITY IN SINGAPORE FROM 1965 TO 1994- THE IMPACT OF HEALTH CARE IN TRANSITION

    Sep 1, 2000, 00:00

  • PCV14- USING THE GENERAL PRACTICE RESEARCH DATABASE TO GENERATE AN 'AT RISK REGISTER' FOR A PRIMARY CARE STROKE PREVENTION PROGRAM

    Sep 1, 2000, 00:00

  • PID5- MEDICO-ECONOMIC MODELLING OF INFLUENZA MANAGEMENT IN EUROPE- METHODOLOGY USED IN FRANCE AND GERMANY

    Sep 1, 2000, 00:00

  • PNH2- EVALUATION OF THE CES-D IN SIX COUNTRIES USING RASCH ITEM RESPONSE THEORY (IRT) ANALYSIS

    Sep 1, 2000, 00:00

  • RS3- QUALITY OF LIFE OF ASTHMATIC PATIENTS WITH DIFFERENT SEVERITY OF DISEASE

    Sep 1, 2000, 00:00

  • PHDE4- PHARMACOECONOMIC EVALUATION OF CALCIPOTRIOL AND UVB IN THE TREATMENT OF PSORIASIS IN THE NETHERLANDS

    Sep 1, 2000, 00:00

  • PNR4- A STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF ALTERNATIVE ACUTE TREATMENT STRATEGIES FOR MIGRAINE- THE DISABILITY IN STRATEGIES FOR CARE (DISC) STUDY

    Sep 1, 2000, 00:00

  • PID14- MODELING PHYSICIAN PREFERENCES IN ANTIBIOTIC CHOICE

    Sep 1, 2000, 00:00

  • PAO8- HOSPITAL COSTS, DAYS, AND POST-ACUTE CARE FOR VERTEBRAL FRACTURES IN WOMEN

    Sep 1, 2000, 00:00

  • PCV26- COST OF CARE AND BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATIENTS IN EMILIA ROMAGNA REGION (ITALY)- RESULTS FROM THE GREAT STUDY

    Sep 1, 2000, 00:00

  • PID4- HOSPITAL ANTIBIOTICS UTILIZATION EVALUATION

    Sep 1, 2000, 00:00

  • PCV21- VARIATION IN MEDICAL RESOURCE UTILIZATION IN THE MANAGEMENT OF PULMONARY EMBOLISM

    Sep 1, 2000, 00:00

  • PMH12- DATA TRIANGULATION IN THE ASSESSMENT OF SUBSTANCE ABUSE TREATMENT OUTCOMES IN ADOLESCENT POPULATIONS

    Sep 1, 2000, 00:00

  • PMH1- THE IMPACT OF DEMENTIA ON THE QUALITY OF LIFE OF CAREGIVERS OF ELDERLY PEOPLE

    Sep 1, 2000, 00:00

  • PMDQ5- MONETARY VALUE OF QUALITY OF LIFE IMPROVEMENTS

    Sep 1, 2000, 00:00

  • Clinical and Economic Outcomes of Coronary Angioplasty Alone or in Combination with Stents in Academic Health Centers- A Retrospective Database Analysis

    Jul 1, 2000, 00:00

  • How Do Italian Pharmacoeconomists Evaluate Indirect Costs?

    Jul 1, 2000, 00:00

  • The Direct Cost of Rheumatoid Arthritis

    Jul 1, 2000, 00:00

  • Data Collection Methods in Prospective Economic Evaluations- How Accurate Are the Results?

    Jul 1, 2000, 00:00

  • The Reliability and Validity of the Impact on Lifestyle Questionnaire in Patients with Acromegaly

    Jul 1, 2000, 00:00

  • Meeting the NICE Requirements- A Markov Model Approach

    Jul 1, 2000, 00:00

  • Modeling the Use of Triple Combination Therapy in Five Countries- Nevirapine, Zidovudine, and Didanosine

    May 1, 2000, 00:00

  • The Use of Conventional Antipsychotic Medications for Patients with Schizophrenia in a Medicaid Population- Therapeutic and Cost Outcomes over 2 Years

    May 1, 2000, 00:00

  • Commentary- Pharmacoeconomics and Outcomes Research- Expanding the Healthcare “Outcomes” Market

    May 1, 2000, 00:00

  • Designing Naturalistic Prospective Studies of Economic and Effectiveness Outcomes Associated with Novel Antipsychotic Therapies

    May 1, 2000, 00:00

  • SF-36 as A Predictor of Health States

    May 1, 2000, 00:00

  • Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data- The Role of Nonrandom Selection and Skewed Data

    May 1, 2000, 00:00

  • PDH19- ANALYSIS OF THE TOTAL COST AND RESOURCES CONSUMED IN CASES OF SINGLE AND CONCURRENT CHRONIC ILLNESS

    Mar 1, 2000, 00:00

  • PCD10- IMPACT OF NEW STATIN DOSES ON MARKET SEGMENTATION

    Mar 1, 2000, 00:00

  • PMT37- BENEFITS OF EARLY MODELING IN DRUG DISCOVERY

    Mar 1, 2000, 00:00

  • DH4- SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP)- IMPACT OF CLINICAL AND FUNCTIONAL STATUS AND TYPE OF MEDICATION TREATMENT ON OUTPATIENT PSYCHIATRIC UTILIZATION

    Mar 1, 2000, 00:00

  • PMH28- QUALITY OF LIFE DIFFERENCES BETWEEN PATIENTS WITH EPISODIC AND TRANSFORMED MIGRAINE

    Mar 1, 2000, 00:00

  • PMT23- MONTE-CARLO SIMULATION AS AN ALTERNATIVE TECHNIQUE IN ADDRESSING THE UNIT COST VARIABILITY ISSUE

    Mar 1, 2000, 00:00

  • PCH7- COST-EFFECTIVENESS OF RITUXIMAB IN RELAPSED, REFRACTORY, LOW-GRADE NON-HODGKINS LYMPHOMA

    Mar 1, 2000, 00:00

  • PHV16- AN UNUSUAL ECONOMIC EVALUATION OF EFAVIRENZ COMPARED TO INDINAVIR

    Mar 1, 2000, 00:00

  • PRS8- ECONOMIC OUTCOMES OF STEROID INHALER USE PATTERNS IN A MANAGED CARE ORGANIZATION

    Mar 1, 2000, 00:00

  • PCD20- ESTIMATING THE EFFECTS OF POLYPHARMACY ON HOSPITALIZATION IN AN ELDERLY CHF MEDICAID POPULATION

    Mar 1, 2000, 00:00

  • PHV27- COSTS AND OUTCOMES OF TREATING FEBRILE NEUTROPENIA IN NINE EUROPEAN COUNTRIES

    Mar 1, 2000, 00:00

  • PRS3- TRENDS IN THE USE OF -AGONIST MEDICATIONS IN BRITISH COLUMBIA- AN ANALYSIS OF BC PHARMACARE DATA

    Mar 1, 2000, 00:00

  • PMT6- MONITORING THE GATEKEEPER- METHODOLOGIES FOR THE DEVELOPMENT OF PROCESS AND OUTCOME MEASURES FOR THE EVALUATION OF IRBS

    Mar 1, 2000, 00:00

  • Ql- CONSUMER AND STAFF VALIDATION OF A SELF-ADMINISTERED HEALTH-RELATED QUALITY OF LIFE INSTRUMENT FOR INDIVIDUALS WITH SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PMT36- LINGUISTIC VALIDATION OF THE WORK LIMITATIONS QUESTIONNAIRE (WLQ)

    Mar 1, 2000, 00:00

  • PMT5- DEVELOPMENT OF MULTI-LANGUAGE PATIENT OUTCOME ASSESSMENTS

    Mar 1, 2000, 00:00

  • PMT33- LINGUISTIC VALIDATION OF THE VASCULAR QUALITY OF LIFE QUESTIONNAIRE (VASCUQOL) IN 8 LANGUAGES

    Mar 1, 2000, 00:00

  • PCD3- INCIDENCE, UTILIZATION OF HEALTH CARE AND COSTS OF STROKE

    Mar 1, 2000, 00:00

  • PHV23- PATIENT ADHERENCE WITH MULTI-DRUG HIV THERAPY- VARIATIONS IN ADHERENCE AND CORRELATION WITH HIV RNA LEVELS

    Mar 1, 2000, 00:00

  • PMH40- ACCESS TO NEW MEDICATIONS TO TREAT SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • DH2- MEDICARES EXTENDED IMMUNOSUPPRESSION COVERAGE IMPROVED MIDDLE-INCOME RENAL GRAFT SURVIVAL

    Mar 1, 2000, 00:00

  • PCD26- A CLOSER LOOK AT HYPERTENSION PRACTICE PATTERNS AND MEDICATION COMPLIANCE

    Mar 1, 2000, 00:00

  • PMH24- TRANSLATIONS OF THE MIGRAINE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (MSQ)- A PSYCHOMETRIC COMPARISON BETWEEN THE ENGLISH, FINNISH, DUTCH, HUNGARIAN, AND SPANISH TRANSLATIONS

    Mar 1, 2000, 00:00

  • PSG12- HOSPITAL COST SAVINGS FROM SEVERITY-ADJUSTED LENGTH OF STAY FOLLOWING SURGERY FOR INTRA-ABDOMINAL INFECTION AND TREATMENT WITH PIPERACILLIN/ TAZOBACTAM OR IMIPENEM/CILASTATIN

    Mar 1, 2000, 00:00

  • PCD24- CONJOINT ANALYSIS COMPARING PREFERENCES FOR TREATMENT OUTCOMES IN HEART FAILURE AND HEALTHY PATIENTS- LONGEVITY VERSUS SYMPTOM RELIEF

    Mar 1, 2000, 00:00

  • PCH14- EFFECTIVENESS OF ERYTHROPOIETIN IN CANCER PATIENTS

    Mar 1, 2000, 00:00

  • PDB4- COST-EFFECTIVENESS OF DIABETIC FOOT ULCER TREATMENT WITH AUTOLOGOUS PLATELET RELEASATE

    Mar 1, 2000, 00:00

  • PDH26- A NATIONAL SURVEY OF DECISION-MAKERS IN MANAGED CARE ON THEIR VIEWS AND USE OF PHARMACOECONOMIC INFORMATION

    Mar 1, 2000, 00:00

  • PAR6- QUALITY OF LIFE MEASUREMENTS AS PREDICTORS OF CHANGE IN THERAPY IN PATIENTS WITH MUSCULOSKELETAL DISORDERS

    Mar 1, 2000, 00:00

  • PHV21- PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF PERTUSSIS BOOSTER VACCINATION OF HOSPITAL STAFF

    Mar 1, 2000, 00:00

  • PMH22- CAN THE BRIEF 'QOLWM' DISCRIMINATE AMONG MIGRAINEURS IN THE COMMUNITY?

    Mar 1, 2000, 00:00

  • PCD25- SYSTEMATIC REVIEW EVIDENCE ON TREATING HYPERTENSION IN OLDER ADULTS

    Mar 1, 2000, 00:00

  • PMH5- THE EFFECT OF RIVASTIGMINE ON THE DIRECT AND INDIRECT COSTS OF ALZHEIMERS DISEASE

    Mar 1, 2000, 00:00

  • PDH31- HEALTH RELATED QUALITY OF LIFE AND REGULATORY ISSUES- COMPARISON OF US AND EUROPEAN INITIATIVES

    Mar 1, 2000, 00:00

  • PCD8- A MODEL COMPARING NITROGLYCERIN FORMULATIONS FOR ACUTE ANGINA EPISODES- ASSESSING THE ECONOMIC ISSUES

    Mar 1, 2000, 00:00

  • PMH16- USE OF ATYPICAL ANTIPSYCHOTIC MEDICATIONS IN A VETERANS POPULATION

    Mar 1, 2000, 00:00

  • PCH17- CONVENIENCE IS THE MAIN REASON WHY OVARIAN CANCER PATIENTS PREFER ORAL REGIMEN

    Mar 1, 2000, 00:00

  • D2- COST UTILITY OF DOCETAXEL VS VINORELBINE OR PACLITAXEL IN ADVANCED BREAST CANCER

    Mar 1, 2000, 00:00

  • MI1- IDENTIFYING FACTORS ASSOCIATED WITH HIGH AND LOW COST ASTHMATICS- OPPORTUNITIES FOR DISEASE MANAGEMENT USING AUTOMATIC INTERACTION DETECTION

    Mar 1, 2000, 00:00

  • PMH38- RESPONSE TO NEFAZODONE, CBASP, AND COMBINED THERAPY- IMPLICATIONS FOR CHRONIC DEPRESSION SEVERITY, FUNCTIONAL STATUS AND ECONOMIC OUTCOMES

    Mar 1, 2000, 00:00

  • PMT2- RELIABILITY OF PRESCRIPTION CLAIMS DATA FOR HEALTH CARE RESEARCH

    Mar 1, 2000, 00:00

  • BT3- THE COMPARATIVE ECONOMIC VALUE OF RALTITREXED AND 5-FU PLUS LEUCOVORIN

    Mar 1, 2000, 00:00

  • PMW3- PRESCRIPTION DRUG USE DURING PREGNANCY- A CLAIMS ANALYSIS

    Mar 1, 2000, 00:00

  • PHV7- MANAGING PNEUMOCYSTOSIS- THE COST OF HOSPITALIZATION IN THE US

    Mar 1, 2000, 00:00

  • PHT4- METHODOLOGICAL ISSUES IN ESTIMATING DISEASE PROGRESSION- IS MARKOV MODEL THE BEST METHOD?

    Mar 1, 2000, 00:00

  • PHT14- IMPROVING THE EVIDENCE BASE OF ECONOMIC ANALYSES

    Mar 1, 2000, 00:00

  • PMT11- METHODOLOGY FOR IDENTIFYING PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES WITHIN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PHV26- EFFECTIVENESS OF ANTIBIOTIC PRESCRIBING AND PATIENT OUTCOMES IN A COMMUNITY SETTING- THE AUSTRALIAN EXPERIENCE

    Mar 1, 2000, 00:00

  • R3- DONEPEZIL USE AND IMPACT ON COST AMONG PATIENTS WITH ALZHEIMERS DISEASE

    Mar 1, 2000, 00:00

  • PCH11- SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY- rhERYTHROPOIETIN (rhEPO) AND QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PDH20- CONTENT ANALYSIS OF PHARMACOECONOMIC ADVERTISING IN SPECIALTY AND PRIMARY CARE JOURNALS

    Mar 1, 2000, 00:00

  • R1- QUANTIFYING THE IMPACT OF INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS (STATINS) AND CYTOCHROME P-450 INTERACTING DRUGS ON HEALTHCARE UTILIZATION- A POPULATION-BASED STUDY

    Mar 1, 2000, 00:00

  • PMT3- PREDICTING DRUG SPENDING- UPDATE AND EVALUATION OF A REVISED CHRONIC DISEASE SCORE

    Mar 1, 2000, 00:00

  • PRN2- COST-EFFECTIVENESS OF BASILIXIMAB, DACLIZUMAB, AND OKT3 AS INDUCTION AGENTS IN KIDNEY TRANSPLANTATION

    Mar 1, 2000, 00:00

  • CEB6- THE IMPORTANCE OF COMPARABLE PATIENT POPULATIONS IN COST-EFFECTIVENESS ANALYSES- TOLTERODINE VERSUS OXYBUTININ XL FOR TREATING OVERACTIVE BLADDER

    Mar 1, 2000, 00:00

  • PDB9- COST OF CONCOMITANT ILLNESSES AMONG PATIENTS WITH HYPERTENSION AND DIABETES

    Mar 1, 2000, 00:00

  • BT1- POSTOPERATIVE PAIN SEVERITY AFTER ABDOMINAL OR ORTHOPEDIC SURGERY- INTERIM RESULTS

    Mar 1, 2000, 00:00

  • PGD1- OVER-THE-COUNTER NSAID USE AND Gl TOXICITY

    Mar 1, 2000, 00:00

  • PRS6- CLASSIFYING ASTHMA SEVERITY BASED ON PRESCRIPTION DRUG CLAIMS

    Mar 1, 2000, 00:00

  • PMH4- ANTIPSYCHOTIC MEDICATION TREATMENT PATTERNS AND ASSOCIATED COST OF CARE OF PATIENTS WITH SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PSG6- COST-MINIMIZATION ANALYSIS OF EPOETIN ALPHA IN THE COMMUNITY HOSPITAL

    Mar 1, 2000, 00:00

  • PMT29- THE INFLUENCE OF STATISTICAL ERRORS ON THE COST-EFFECTIVENESS OF TREATMENTS FOLLOWING A PHASE-MI CLINICAL TRIAL

    Mar 1, 2000, 00:00

  • PMH29- THE IMPACT OF AN OVER-THE-COUNTER MIGRAINE MEDICATION ON PATIENT QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PCD16- COST-EFFECTIVENESS OF TIROFIBAN PLUS HEPARIN AS COMPARED WITH HEPARIN ONLY IN TREATING UNSTABLE ANGINA

    Mar 1, 2000, 00:00

  • D3- A PHARMACOECONOMIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF TROVAFLOXACIN COMPARED TO CEFTAZIDIME FOR NOSOCOMIAL PNEUMONIA IN A PUBLIC HOSPITAL SETTING IN HONG KONG

    Mar 1, 2000, 00:00

  • POS4- COST-EFFECTIVENESS OF SCREENING FOR OSTEOPOROSIS IN ELDERLY WOMEN

    Mar 1, 2000, 00:00

  • PSG8- LONG-TERM OUTCOMES AND RESOURCE USE ASSOCIATED WITH MYOMECTOMY

    Mar 1, 2000, 00:00

  • D4- ECONOMIC ANALYSIS OF WARFARIN IN OUTPATIENTS WITH ATRIAL FIBRILLATION- INNOVATOR VERSUS GENERIC

    Mar 1, 2000, 00:00

  • PHV2- THE BURDEN OF RESPIRATORY SYNCTIAL VIRUS (RSV) HOSPITALIZATIONS IN THE US

    Mar 1, 2000, 00:00

  • PDB2- THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE I DIABETES MELLITUS

    Mar 1, 2000, 00:00

  • Q4- MINIMUM MEANINGFUL DIFFERENCE SCORES FOR THE IRRITABLE BOWEL SYNDROME QUALITY OF LIFE QUESTIONNAIRE (IBSQOL)

    Mar 1, 2000, 00:00

  • CEB1- PHARMACOGENOMICS- EVALUATING THE ECONOMIC IMPACT

    Mar 1, 2000, 00:00

  • PDH21- PRE-POST AND BETWEEN GROUP DIFFERENCES IN PATIENT OUTCOMES IN A PHARMACEUTICAL CARE INTERVENTION PROJECT

    Mar 1, 2000, 00:00

  • PGD4- THE CLINICAL AND ECONOMIC IMPACT OF COMPETING MANAGEMENT STRATEGIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    Mar 1, 2000, 00:00

  • PMT22- TREATMENT SATISFACTION IN OUTCOMES RESEARCH- AN OVERVIEW OF STUDY MEASURES

    Mar 1, 2000, 00:00

  • DUC2- INSURANCE CLAIMS COSTS FOR OVERACTIVE BLADDER IN ADULTS

    Mar 1, 2000, 00:00

  • MI4- A FRAMEWORK FOR COST-EFFECTIVENESS ANALYSIS FROM CLINICAL TRIAL DATA

    Mar 1, 2000, 00:00

  • PWP1- COMPARATIVE BURDEN OF ILLNESS AT TWO LARGE US COMPANIES

    Mar 1, 2000, 00:00

  • PMH33- NEUROLEPTIC DRUG EXPOSURE AND TARDIVE DYSKINESIA- A RECORDS-BASED CASE-CONTROL STUDY

    Mar 1, 2000, 00:00

  • PDH27- THE SATISFACTION AND ECONOMIC EVALUATION OF CONVERTING A TRADITIONAL HOSPITAL SYSTEM USING A UNIT DOSE SYSTEM, AT A HOSPITAL IN BARBADOS, WEST INDIES

    Mar 1, 2000, 00:00

  • PHV12- MANAGEMENT STRATEGIES FOR RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN THE TREATMENT OF HEPATITIS C- CLINICAL AND ECONOMIC IMPLICATIONS

    Mar 1, 2000, 00:00

  • PCD11- THE COST-EFFECTIVENESS ANALYSIS AS A SUBSTANTIATION OF DIAGNOSTIC AND TREATMENT OF EARLY STAGE OF HEART FAILURE

    Mar 1, 2000, 00:00

  • PMH15- UTILIZATION OF ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA IN A MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PGD2- IMPROVED DRUG COMPLIANCE USING EDUCATION AFFECTS MEDICAL UTILIZATION AND QUALITY OF LIFE FOR PEPTIC ULCER DISEASE PATIENTS

    Mar 1, 2000, 00:00

  • PMH1O- A MODEL TO PERFORM ECONOMIC EVALUATIONS OF INTERVENTIONS FOR ACUTE MUSCULAR LOW BACK PAIN

    Mar 1, 2000, 00:00

  • PCH9- PATTERNS OF EPOETIN ALPHA UTILIZATION IN ANEMIC CANCER PATIENTS

    Mar 1, 2000, 00:00

  • PDH3- PHARMACEUTICAL PRICE CONTROLS AND POSITIVE DRUG LIST EFFECTS ON TOTAL AND SOCIAL INSURANCE EXPENDITURES

    Mar 1, 2000, 00:00

  • PCD23- UNADJUSTED INPATIENT COSTS AND MORTALITY FOR FOUR CEREBROVASCULAR EVENTS FOR PATIENTS TREATED AT COMMUNITY TEACHING AND NONTEACHING HOSPITALS

    Mar 1, 2000, 00:00

  • PSG5- THE ECONOMIC IMPACT OF THE USE OF PERFLUORO-N-OCTANE DURING RETINAL DETACHMENT SURGERY

    Mar 1, 2000, 00:00

  • PHH7- COST-EFFECTIVENESS OF ATYPICAL ANTIPSYCHOTICS IN CHRONIC SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PRS10- ANNUAL COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION

    Mar 1, 2000, 00:00

  • PMH8- COST-EFFECTIVENESS OF STRATIFIED CARE IN THE MANAGEMENT OF MIGRAINE

    Mar 1, 2000, 00:00

  • PCD22- THE EFFECT OF NATIONALITY ON HEALTH-RELATED QUALITY OF LIFE IN THE GUSTO-I ANGIOGRAPHIC TRIAL

    Mar 1, 2000, 00:00

  • PWP3- CONSUMER PREFERENCES FOR DENTAL ANESTHESIA- PUTTING YOUR MONEY WHERE YOUR MOUTH IS

    Mar 1, 2000, 00:00

  • Q3- HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN AFRICAN AMERICAN MEN WITH PROSTATE CANCER- DATA FROM CaPSURE

    Mar 1, 2000, 00:00

  • PRN6- DEVELOPING A SPECIFIC HRQL INSTRUMENT FOR OVERACTIVE BLADDER

    Mar 1, 2000, 00:00

  • PHW4- MEASUREMENT PROPERTIES OF QUALITY OF LIFE INSTRUMENTS IN ERECTILE DYSFUNCTION (ED)- A REVIEW OF PUBLISHED RESULTS

    Mar 1, 2000, 00:00

  • PRN1- OVERACTIVE BLADDER COST OF ILLNESS- ANALYSIS OF MEDI-CAL CLAIMS

    Mar 1, 2000, 00:00

  • PHT7- THE FRENCH HEALTH UTILITIES INDEX MARK 3

    Mar 1, 2000, 00:00

  • PMH30- MODELING LENGTH OF PRESCRIPTION THERAPY FOR DEPRESSION PATIENTS

    Mar 1, 2000, 00:00

  • PSS9- CLINICAL AND ECONOMIC OUTCOMES OF CORONARY ANGIOPLASTY ALONE OR IN COMBINATION WITH STENTS IN ACADEMIC HEALTH CENTERS- A RETROSPECTIVE DATABASE ANALYSIS

    Mar 1, 2000, 00:00

  • PRS7- DRIVERS OF DIAGNOSIS OF OBSTRUCTIVE LUNG DISEASE, BY STAGE OF SEVERITY

    Mar 1, 2000, 00:00

  • PHT8- DEVELOPMENT OF A NEW SCORING OF THE WOMENS HEALTH QUESTIONNAIRE (WHQ)

    Mar 1, 2000, 00:00

  • CEB2- COST-EFFECTIVENESS OF MENINGOCOCCAL VACCINE IN THE UK

    Mar 1, 2000, 00:00

  • PHV5- EFFECTIVENESS AND COSTS OF ANTIBIOTICS IN THE AMBULATORY TREATMENT OF RESPIRATORY TRACT INFECTIONS

    Mar 1, 2000, 00:00

  • PHV30- COSTS AND OUTCOMES OF A RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS PROGRAM IN A MEDICAID MANAGED CARE ORGANIZATION

    Mar 1, 2000, 00:00

  • PCN3- PREDICTORS OF CERVICAL CANCER INPATIENT ADMISSION COSTS BY STAGE

    Mar 1, 2000, 00:00

  • PDH33- EVALUATION AND TREATMENT OF SHORT STATURE- NATIONAL COOPERATIVE GROWTH STUDY (NCGS) EXPERIENCE

    Mar 1, 2000, 00:00

  • PCD5- COSTS OF LEFT VENTRICULAR ASSIST DEVICE VERSUS POSITIVE INOTROPIC THERAPY AS A BRIDGE TO HEART TRANSPLANT

    Mar 1, 2000, 00:00

  • PMT24- 'CAMOUFLAGED SAMPLING' USING BC MINISTRY OF HEALTH DATA- A METHOD OF RECRUITING SUBJECTS WHILE PRESERVING DATA PRIVACY

    Mar 1, 2000, 00:00

  • PRN9- THE INFLUENCE OF PHARMACEUTICAL CARE SERVICES ON THE BLOOD PRESSURE OF RENAL TRANSPLANT PATIENTS

    Mar 1, 2000, 00:00

  • PCN6- COST-EFFECTIVENESS OF GENETIC TESTING IN HEREDITARY NON-POLYPOSIS COLORECTAL CANCER

    Mar 1, 2000, 00:00

  • PMT25- COMPARATIVE ECONOMETRIC MODELS OF MEDICAL COSTS

    Mar 1, 2000, 00:00

  • BT4- COST-EFFECTIVENESS OF HIGH VERSUS LOW DOSE ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACEIs) IN THE TREATMENT OF CHRONIC HEART FAILURE (CHF)- AN ECONOMIC ANALYSIS OF THE US ASSESSMENT OF TREATMENT WITH LISINOPRIL AND SURVIVAL (ATLAS) TR ...

    Mar 1, 2000, 00:00

  • PHV11- COST-MINIMIZATION ANALYSIS OF AZITHROMYCIN IV/PO VERSUS CEFUROXIME IV/PO +/- ERYTHROMYCIN IV/PO FOR COMMUNITY-ACQUIRED PNEUMONIA

    Mar 1, 2000, 00:00

  • PHV14- A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE

    Mar 1, 2000, 00:00

  • CAN4- IS PRIOR COMMUNITY ANTIBIOTIC TREATMENT OF PATIENTS HOSPITALISED WITH LOWER RESPIRATORY TRACT INFECTION ASSOCIATED WITH REDUCED IN-HOSPITAL MORTALITY AND LENGTH OF STAY?

    Mar 1, 2000, 00:00

  • PAR3- REDUCED UTILIZATION OF ANTIULCERANT DRUGS WITH CELECOXIB- FINDINGS OF THE PAINLESS TRIAL

    Mar 1, 2000, 00:00

  • PDB8- HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN TYPE 2 DIABETES

    Mar 1, 2000, 00:00

  • PDH2- FACTORS RELATED TO PRESCRIPTION DRUG EXPENDITURE GROWTH- VOLUME VS. PRICE

    Mar 1, 2000, 00:00

  • PDH4- TECHNOLOGY ASSESSMENT IN THE US- WHAT DO PAYERS UNDERSTAND AND WHAT INFORMATION DO THEY WANT?

    Mar 1, 2000, 00:00

  • PDH32- COST IMPACT OF A PRESCRIPTION BENEFIT CHANGE IN A MEDICARE MANAGED CARE PLAN

    Mar 1, 2000, 00:00

  • PCN1- OUTCOMES AND COSTS OF ACUTE MYELOID LEUKEMIA OVER ONE YEAR FOLLOWING DIAGNOSIS- AN ANALYSIS OF SEER-MEDICARE DATA

    Mar 1, 2000, 00:00

  • PMT30- PREFERENCE BASED INDEX FROM THE SF-12

    Mar 1, 2000, 00:00

  • PSG4- TRAUMATIC COLON INJURIES- DIFFERENCE IN HOSPITAL COSTS BY TYPE OF SURGICAL REPAIR

    Mar 1, 2000, 00:00

  • PDB7- TREATMENT COSTS OF TYPE-2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SELECTED CARDIOVASCULAR COMORBIDITIES

    Mar 1, 2000, 00:00

  • PAR4- NSAID UTILIZATION AMONG COMMERCIALLY INSURED MEMBERS IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PHV1O- A PRELIMINARY STUDY- THE PHARMACOECONOMIC PROFILE OF ANTIBIOTIC USE IN TURKEY

    Mar 1, 2000, 00:00

  • POS5- PREVALENCE OF PHARMACOTHERAPY FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00

  • PSG1- INPATIENT UTILIZATION OF MEDICAL SERVICES ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE

    Mar 1, 2000, 00:00

  • PAR7- THE LONGTERM SAFETY AND EFFECTIVENESS OF CYCLOSPORINE IN PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS (RA)

    Mar 1, 2000, 00:00

  • PMT35- VALUING NON-WORKPLACE PRODUCTIVITY LOST IN MIGRAINEURS- HUMAN CAPITAL APPROACH AND REPLACEMENT COST METHOD

    Mar 1, 2000, 00:00

  • PCH15- COST-EFFECTIVENESS OF TAMOXIFEN IN BREAST CANCER RISK REDUCTION

    Mar 1, 2000, 00:00

  • PDH9- DRUG AND EXAMINATION IN RELATION TO THE TOTAL THERAPY COSTS-A COST MANAGEMENT DILEMMA?

    Mar 1, 2000, 00:00

  • PCN16- VALIDITY OF THE TIME-TRADE OFF TECHNIQUE IN DETERMINING PREFERENCES FOR THE TREATMENT OF PROSTATE CANCER

    Mar 1, 2000, 00:00

  • PMH14- USE OF OLANZAPINE AND RISPERIDONE AT BASELINE IN A PROSPECTIVE STUDY OF THE COURSE OF TREATMENT FOR SCHIZOPHRENIA

    Mar 1, 2000, 00:00

  • PHV29- VARIABILITY IN THE CRITERIA FOR EARLY SWITCH AND EARLY DISCHARGE IN COMMUNITY-ACQUIRED PNEUMONIA- A SYSTEMATIC REVIEW OF THE LITERATURE

    Mar 1, 2000, 00:00

  • PDH23- RELEVANCE OF PHARMACOECONOMICS AND HEALTH OUTCOMES INFORMATION TO HEALTH CARE DECISION-MAKERS IN THE UNITED STATES

    Mar 1, 2000, 00:00

  • PMH41- PATTERNS OF ANTIDEPRESSANT USE AND CONCOMITANT PSYCHOTHERAPEUTIC AGENTS

    Mar 1, 2000, 00:00

  • DUC4- HIGH USERS OF 2-AGONISTS- ARE MEDICAID RECIPIENTS BEING TREATED ACCORDING TO NATIONAL ASTHMA GUIDELINES?

    Mar 1, 2000, 00:00

  • PDH7- THE IMPACT OF LOCUS OF CONTROL ON COMPLIANCE

    Mar 1, 2000, 00:00

  • PDH28- A DRUG COST MODEL FOR A CAPITATED PATIENT POPULATION WITHIN AN INTEGRATED HEALTH CARE SYSTEM

    Mar 1, 2000, 00:00

  • PCD2- ASSESSING THE BURDEN OF ILLNESS IN ELDERLY VERSUS YOUNGER ACUTE CORONARY SYNDROME PATIENTS

    Mar 1, 2000, 00:00

  • POS3- THE SIMPLE CALCULATED OSTEOPOROSIS RISK ESTIMATION (SCORE) DOES NOT ALLOW IDENTIFICATION OF BELGIAN WOMEN WITH A HIGH RISK OF OSTEOPOROSIS

    Mar 1, 2000, 00:00

  • PAR5- COMPARING THE HEALTH RELATED QUALITY OF LIFE OUTCOMES OF TREATMENT FOR EARLY RHEUMATOID ARTHRITIS

    Mar 1, 2000, 00:00

  • S4- METHODS FOR COMPARING AREAS UNDER RECEIVER OPERATING CHARACTERISTIC CURVES- APPLICATION IN SCREENING ACCURACY FOR DEPRESSION

    Mar 1, 2000, 00:00

  • CAN2- SHORTER HOSPITAL LENGTH OF STAY FOR CORONARY ANGIOPLASTY PATIENTS WHO RECEIVE ABCIXIMAB VERSUS EPTIFIBATIDE ORTIROFIBAN

    Mar 1, 2000, 00:00

  • ICP1- INCORPORATING MEASUREMENT OF INDIRECT COSTS IN THE EVALUATION OF AN ASTHMA HEALTH MANAGEMENT PROGRAM

    Mar 1, 2000, 00:00

  • PMT9- ASSESSING THE COST-EFFECTIVENESS RATIO OF A NEW ANTI-PLATELET AGENT- METHODOLOGIC ISSUES

    Mar 1, 2000, 00:00

  • BT2- DIRECT COSTS OF OBESITY IN PORTUGAL

    Mar 1, 2000, 00:00

  • PAR1- THE BURDEN OF EARLY RHEUMATOID ARTHRITIS ON HEALTH RELATED QUALITY OF LIFE

    Mar 1, 2000, 00:00

  • PMW5- A PHARMACOECONOMIC EVALUATION OF HORMONE REPLACEMENT THERAPY IN THE UNITED KINGDOM AND BELGIUM

    Mar 1, 2000, 00:00

  • PDB3- THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE 2 DIABETES MELLITUS

    Mar 1, 2000, 00:00

  • PRS4- IDENTIFYING PREDICTORS OF THE ASTHMA-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE-AMERICAN ADULTS (AQLQ-NAA)

    Mar 1, 2000, 00:00

  • PWP2- A METHODOLOGY TO MEASURE PRODUCTIVITY OF HEALTH OUTCOMES GROUPS

    Mar 1, 2000, 00:00

  • PMH12- THE EFFICIENCY OF DRUG TREATMENT IN FIRST EPISODE SCHIZOPHRENIA- TREATMENT GUIDELINES IN THE UK

    Mar 1, 2000, 00:00

  • PMH42- THE IMPACT OF ADDING SSRI ANTIDEPRESSANTS TO THE MEDICAID FORMULARY IN CALIFORNIA

    Mar 1, 2000, 00:00

  • PCD19- RELATIONSHIP BETWEEN DAILY DOSE FREQUENCY AND ADHERENCE TO ANTIHYPERTENSIVE PHARMACOTHERAPY- UPDATE OF A META-ANALYSIS

    Mar 1, 2000, 00:00

  • PMT20- THE USE OF ECONOMIC ANALYSES IN PRACTICE GUIDELINE DEVELOPMENT

    Mar 1, 2000, 00:00

  • PHV6- ECONOMIC EVALUATION OF A SAFETY DEVICE FOR SUBCUTANEOUS INJECTIONS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH)

    Mar 1, 2000, 00:00

  • PCD4- THE IMPACT OF SECONDARY EVENTS ON THE COST OF ACUTE MYOCARDIAL INFARCTION

    Mar 1, 2000, 00:00

  • PMH23- HOW MUCH CHANGE IN QUALITY OF LIFE AND SYMPTOM SCORES REPRESENTS A DETECTABLE DIFFERENCE FOR SCHIZOPHRENIA PATIENTS?

    Mar 1, 2000, 00:00

  • CAN1- COMPARISON OF COSTS OF ASTHMA TREATMENT BETWEEN PATIENTS TREATED WITH ANTI-INFLAMMATORIES VERSUS BRONCHODILATORS

    Mar 1, 2000, 00:00

  • PDH5- HEALTH CARE EXPENDITURE IN AN HMO BEFORE AND AFTER AN EXCLUSIVE PHARMACY PARTNERSHIP

    Mar 1, 2000, 00:00

  • PDH22- MODELLING THE BENEFITS OF VERTEPORFIN THERAPY IN MACULAR DEGENERATION

    Mar 1, 2000, 00:00

  • PRS5- IMPACT OF INHALED CORTICOSTEROIDS (FLUTICASONE PROPIONATE) ON ECONOMIC OUTCOMES IN A MANAGED CARE ENVIRONMENT

    Mar 1, 2000, 00:00
  • «
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179 (current)
  • 180
  • »